[go: up one dir, main page]

TR200001253T2 - Tümöre özel antijenler - Google Patents

Tümöre özel antijenler

Info

Publication number
TR200001253T2
TR200001253T2 TR2000/01253T TR200001253T TR200001253T2 TR 200001253 T2 TR200001253 T2 TR 200001253T2 TR 2000/01253 T TR2000/01253 T TR 2000/01253T TR 200001253 T TR200001253 T TR 200001253T TR 200001253 T2 TR200001253 T2 TR 200001253T2
Authority
TR
Turkey
Prior art keywords
tumor
specific antigens
specific
diagnosis
useful
Prior art date
Application number
TR2000/01253T
Other languages
English (en)
Inventor
Anichini Andrea
Parmiani Giorgio
Sensi Marialuisa
Traversari Catia
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of TR200001253T2 publication Critical patent/TR200001253T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Tümöre özel polipeptidik bir antijen, tümör hastaliklariyla ilgili teshis ve terapötik kullanim için yaralidir.
TR2000/01253T 1997-11-06 1998-11-02 Tümöre özel antijenler TR200001253T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97119404 1997-11-06

Publications (1)

Publication Number Publication Date
TR200001253T2 true TR200001253T2 (tr) 2000-11-21

Family

ID=8227582

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/01253T TR200001253T2 (tr) 1997-11-06 1998-11-02 Tümöre özel antijenler

Country Status (11)

Country Link
EP (1) EP1029050A1 (tr)
JP (1) JP2001522603A (tr)
KR (1) KR20010024585A (tr)
CN (1) CN1278865A (tr)
AR (1) AR017562A1 (tr)
AU (1) AU743066B2 (tr)
BR (1) BR9813981A (tr)
CA (1) CA2309557A1 (tr)
TR (1) TR200001253T2 (tr)
WO (1) WO1999024566A1 (tr)
ZA (1) ZA9810130B (tr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
RS64230B1 (sr) 2011-05-24 2023-06-30 BioNTech SE Individualizovane vakcine protiv kancera
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
CN107076762B (zh) 2014-09-10 2021-09-10 豪夫迈·罗氏有限公司 免疫原性突变体肽筛选平台
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
KR102526538B1 (ko) 2015-06-10 2023-04-28 이뮤너티바이오, 인크. 암을 치료하기 위한 변형된 nk-92 세포
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
SG11201807257VA (en) * 2016-03-03 2018-09-27 Roussy Inst Gustave Ptps-based vaccines against cancer
EP3519562A4 (en) 2016-09-29 2020-03-25 Nantkwest, Inc. NK-92 HLA CLASS I DEFICIENT CELLS WITH REDUCED IMMUNOGENICITY
WO2018129346A1 (en) 2017-01-06 2018-07-12 Nantkwest, Inc. Genetically modified nk-92 cells with decreased cd96/tigit expression
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
WO2019075112A1 (en) * 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
WO2019089813A1 (en) 2017-11-01 2019-05-09 Nantkwest, Inc. Nk-92 cells to stimulate anti-cancer vaccine
DE112019000608B4 (de) 2018-01-31 2021-05-06 Nantkwest, Inc. Verwendung von 5 % humanalbumin in wasch- und erntemedien
EP3743446A1 (en) 2018-03-12 2020-12-02 Nantkwest, Inc. Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
EP3797155B1 (en) 2018-05-22 2022-06-15 ImmunityBio, Inc. Optimization of nk-92 cell growth using poloxamer
IL321548A (en) 2018-05-22 2025-08-01 Immunitybio Inc Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
EP3797156A1 (en) 2018-05-22 2021-03-31 Nantkwest, Inc. Basal media for growing nk-92 cells
US20210267190A1 (en) 2018-07-10 2021-09-02 Nantkwest, Inc. Cryopreservation
KR102721222B1 (ko) 2018-07-10 2024-10-24 이뮤너티바이오, 인크. 제대혈로부터 cik nkt 세포의 생성
EP4678241A2 (en) 2018-08-01 2026-01-14 ImmunityBio, Inc. A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies
WO2020027832A1 (en) 2018-08-01 2020-02-06 Nantkwest, Inc. Chemokine responsive activated natural killer cells with secondary homing activation for verified targets
WO2020028654A1 (en) 2018-08-01 2020-02-06 Nantkwest, Inc. Combined invasion and cytotoxicity assay using chemokine secreting target cells
US12109238B2 (en) 2018-11-06 2024-10-08 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells
WO2020096646A1 (en) 2018-11-06 2020-05-14 Nantkwest, Inc. Chimeric antigen receptor-modified nk-92 cells
CA3117936A1 (en) 2018-11-26 2020-06-04 Immunitybio, Inc. Il-2 dependent nk-92 cells with stable fc receptor expression
CN110491450B (zh) * 2019-08-23 2023-05-16 深圳市新合生物医疗科技有限公司 肿瘤新生抗原预测平台及其应用
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
US20240415964A1 (en) 2021-11-02 2024-12-19 Immunitybio, Inc. Natural killer cells for chordoma therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein

Also Published As

Publication number Publication date
KR20010024585A (ko) 2001-03-26
AR017562A1 (es) 2001-09-12
AU2151899A (en) 1999-05-31
WO1999024566A1 (en) 1999-05-20
EP1029050A1 (en) 2000-08-23
CA2309557A1 (en) 1999-05-20
JP2001522603A (ja) 2001-11-20
AU743066B2 (en) 2002-01-17
CN1278865A (zh) 2001-01-03
ZA9810130B (en) 1999-05-06
BR9813981A (pt) 2000-09-26

Similar Documents

Publication Publication Date Title
TR200001253T2 (tr) Tümöre özel antijenler
CY1110256T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
ATE218143T1 (de) Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität
FI864037A7 (fi) Monoklonaaliset vasta-aineet ihmisen rintasyöpää vastaan.
IL132468A0 (en) A kit for inducing immune response against a tumor or a disease caused by an infection agent
AU2342897A (en) Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
IL144265A0 (en) Use of antibodies for the vaccination against cancer
BR9612619A (pt) Método e composição para reconformar antígenos multiepitópicos para iniciar uma resposta imunológica
EP1706423B8 (en) Therapeutic and diagnostic anti-hsp 70 antibodies
OA08485A (fr) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
ATE205532T1 (de) Zellzyklus-unabhängige, gliomaoberflach- spezifische, menschliche monoklonale antikörper
WO1997011667A3 (en) Therapeutic applications using horse serum
ES8704082A1 (es) Procedimiento para preparar un agente terapeutico a base de celulas tumorales humanas y eventualmente, neuraminidasa.
EP0585364A4 (en) THE ANTIQUE CTAA 81AV78 RECOGNIZED BY THE MONOCLONAL HUMAN ANTIBODY 81AV78.
DE59710330D1 (de) Hybridzelle und deren Verwendung zur Herstellung eines Arzneimittels zur Induktion einer Tumorimmunität
AU2002326318A1 (en) Targeting tumor cell antigens: antibodies useful for the diagnosis, prognosis, and treatment of cancer
DE59712247D1 (de) Mammakarzinom-assoziiertes gen
IT1254147B (it) Metodo di rivelazione di marcatori tumorali.
ATE320818T1 (de) Mittel zur identifizierung und therapie metastasierender tumore
WO1999043815A3 (en) Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof
BR0007814A (pt) Uso de anticorpos para a vacinação contra câncer
DK175091D0 (da) Human tumor associated antigens, ca-ou2 and ca-ou3